Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Aclaris Therapeutics Trading Down 1.4 %
Shares of NASDAQ:ACRS traded down $0.25 during midday trading on Tuesday, hitting $17.75. The company's stock had a trading volume of 18,134 shares, compared to its average volume of 251,547. The business's 50 day moving average is $15.14 and its two-hundred day moving average is $14.40. Aclaris Therapeutics has a 12-month low of $9.26 and a 12-month high of $19.97.
Aclaris Therapeutics (NASDAQ:ACRS - Get Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.05. Aclaris Therapeutics had a negative return on equity of 40.14% and a negative net margin of 1,355.98%. On average, sell-side analysts expect that Aclaris Therapeutics will post -1.49 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on ACRS shares. William Blair reaffirmed an "outperform" rating on shares of Aclaris Therapeutics in a research note on Wednesday, May 11th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Aclaris Therapeutics in a research note on Monday, August 1st. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $38.00.
Insiders Place Their Bets
In other Aclaris Therapeutics news, Director Andrew N. Schiff sold 19,565 shares of the firm's stock in a transaction on Friday, June 17th. The stock was sold at an average price of $15.14, for a total transaction of $296,214.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.70% of the stock is currently owned by company insiders.